

# CITATION REPORT

List of articles citing

Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias

DOI: 10.3324/haematol.2009.014696  
Haematologica, 2010, 95, 557-66.

**Source:** <https://exaly.com/paper-pdf/49028977/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
241	Update on the use of deferasirox in the management of iron overload. <b>2009</b> , 5, 857-68		20
240	Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. <b>2010</b> , 116, 2448-54		52
239	Pathogenesis and management of iron toxicity in thalassemia. <b>2010</b> , 1202, 1-9		97
238	Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. <b>2010</b> , 84, 825-89		292
237	A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. <b>2010</b> , 52, 1671-779		72
236	Iron chelation therapy for patients with sickle cell disease and iron overload. <b>2010</b> , 85, 782-6		12
235	Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. <b>2010</b> , 34, 1143-50		136
234	Renal complications in transfusion-dependent beta thalassaemia. <b>2010</b> , 24, 239-44		56
233	Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia. <b>2010</b> , 151, 504-8		25
232	Deferasirox--current knowledge and future challenges. <b>2010</b> , 1202, 87-93		9
231	New treatments for myelodysplastic syndromes. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , <b>2010</b> , 2, e2010021	3.2	4
230	Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients. <b>2010</b> , 13, 559-70		9
229	Cardiac events and cardiac T2* in Egyptian children and young adults with beta-thalassemia major taking deferoxamine. <b>2010</b> , 3, 174-8		4
228	Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. <b>2010</b> , 9, 633-41		26
227	Acute renal failure and Fanconi syndrome due to deferasirox. <b>2010</b> , 25, 2376-8		45
226	Update on iron chelators in thalassemia. <b>2010</b> , 2010, 451-5		37
225	Deferasirox for managing iron overload in people with myelodysplastic syndrome. <b>2010</b> , CD007461		3

224	Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies. <b>2010</b> , 24, 1109-30	36
223	Iron-chelating therapy for transfusional iron overload. <b>2011</b> , 364, 146-56	245
222	Improvement in liver pathology of patients with $\beta$ thalassemia treated with deferasirox for at least 3 years. <b>2011</b> , 141, 1202-11, 1211.e1-3	66
221	$\beta$ thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. <b>2011</b> , 118, 4321-30	138
220	Iron chelation in thalassemia: time to reconsider our comfort zones. <b>2011</b> , 4, 17-26	26
219	Iron deficiency anemia, anemia of chronic disorders and iron overload. <b>2011</b> , 173-195	3
218	Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias. <b>2011</b> , 41, 516-24	37
217	Blood transfusion usage among adults with sickle cell disease - a single institution experience over ten years. <b>2011</b> , 152, 766-70	45
216	Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. <b>2011</b> , 154, 387-97	59
215	Chelation treatment in sickle-cell-anaemia: much ado about nothing?. <b>2011</b> , 154, 545-55	26
214	New approaches to managing anaemia. <b>2011</b> , 6, 241-244	
213	Modern management of thalassemia. <b>2011</b> , 6, 432-437	1
212	Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. <b>2011</b> , 87, 338-48	26
211	Importance of optimal dosing $\geq 0$ mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with $\beta$ thalassaemia. <b>2011</b> , 87, 355-65	24
210	Hemojuvelin hemochromatosis receiving iron chelation therapy with deferasirox: improvement of liver disease activity, cardiac and hematological function. <b>2011</b> , 87, 467-9	13
209	Deferasirox effectively decreases iron burden in patients with double heterozygous HbS/ $\beta$ thalassemia. <b>2011</b> , 90, 11-5	9
208	Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox. <b>2011</b> , 93, 319-328	11
207	Challenges of adherence and persistence with iron chelation therapy. <b>2011</b> , 94, 453-60	37

206	The relevance of iron overload and the appropriateness of iron chelation therapy for patients with myelodysplastic syndromes: a dialogue and debate. <b>2011</b> , 6, 136-44	14
205	Iron in sickle-cell disease: what have we learned over the years?. <b>2011</b> , 56, 182-90	15
204	Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent $\beta$ -thalassemia. <b>2011</b> , 56, 420-4	24
203	Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review. <b>2011</b> , 35, 566-70	48
202	Recent advances in $\beta$ -thalassemias. <b>2011</b> , 3, e17	26
201	Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. <b>2011</b> , 118, 884-93	150
200	A case of well-tolerated and safe deferasirox administration during the first trimester of a spontaneous pregnancy in an advanced maternal age thalassemic patient. <b>2011</b> , 125, 222-4	3
199	Real-world use of iron chelators. <b>2011</b> , 2011, 451-8	45
198	Managing unresponsiveness or intolerance to deferasirox therapy: a tale of two doses. <b>2011</b> , 4, 411-4	2
197	Iron chelation therapy for transfusional iron overload: a swift evolution. <b>2011</b> , 35, 565-73	8
196	Eisenchelator-Therapie mit Deferasirox: Therapiebeginn und Dosisoptimierung. <b>2012</b> , 33, 29-33	1
195	Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. <i>Haematologica</i> , <b>2012</b> , 97, 1364-71	6.6 135
194	Deferasirox: pharmacokinetics and clinical experience. <b>2012</b> , 8, 123-34	24
193	Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in $\beta$ -Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial. <b>2012</b> , 2012, 297641	39
192	Treating thalassemia major-related iron overload: the role of deferiprone. <b>2012</b> , 3, 119-29	36
191	Chelating agents for the treatment of systemic iron overload. <b>2012</b> , 19, 2816-27	76
190	Iranian experience of deferasirox (Exjade(®)) in transfusion-dependent patients with iron overload: what is the most effective dose based on serum ferritin levels?. <b>2012</b> , 17, 367-71	4
189	Efficacy of deferasirox in North Indian $\beta$ -thalassemia major patients: a preliminary report. <b>2012</b> , 34, 51-3	4

188	Deferasirox therapy in children with Fanconi aplastic anemia. <b>2012</b> , 34, 247-51	12
187	Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. <b>2012</b> , 120, 970-7	95
186	How I treat transfusional iron overload. <b>2012</b> , 120, 3657-69	138
185	Design of iron chelators with therapeutic application. <b>2012</b> , 41, 6371-89	110
184	Deferasirox for managing iron overload in people with thalassaemia. <b>2012</b> , CD007476	19
183	[Post-transfusional iron overload, iron loading anemia]. <b>2012</b> , 33 Suppl 1, S15-8	1
182	Discovery of benzylisothiourreas as potent divalent metal transporter 1 (DMT1) inhibitors. <b>2012</b> , 22, 5108-13	20
181	Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox. <b>2012</b> , 53, 643-8	48
180	Two-year analysis of efficacy and safety of deferasirox treatment for transfusional iron overload in sickle cell anemia patients. <b>2012</b> , 128, 113-8	9
179	A new tool for the assessment of satisfaction with iron chelation therapy (ICT-Sat) for patients with $\beta$ thalassemia major. <b>2012</b> , 58, 910-5	5
178	Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia. <b>2012</b> , 49, 281-5	7
177	Prognostic significance of serum ferritin level at diagnosis in myelodysplastic syndrome. <b>2012</b> , 95, 527-34	27
176	Iron chelation therapy in the management of transfusion-related cardiac iron overload. <b>2012</b> , 52, 2256-68	13
175	New updating into hemoglobinopathies. <b>2012</b> , 34, 559-65	15
174	Observational study comparing long-term safety and efficacy of Deferasirox with Desferrioxamine therapy in chelation-naïve children with transfusional iron overload. <b>2012</b> , 88, 431-8	18
173	Renal aspects of thalassaemia a changing paradigm. <b>2012</b> , 89, 187-97	35
172	Oxidative stress and antioxidant capacity in sickle cell anaemia patients receiving different treatments and medications for different periods of time. <b>2012</b> , 91, 479-89	20
171	Sickle-Cell Disease and Stroke: Evidence-Based Neuroimaging. <b>2013</b> , 167-187	

170	Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy. <b>2013</b> , 92, 211-9	30
169	Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia. <b>2013</b> , 6, 495-509	8
168	Supportive care in severe and very severe aplastic anemia. <b>2013</b> , 48, 168-73	34
167	When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?. <b>2013</b> , 26, 431-44	28
166	Deferasirox treatment improved hematopoiesis and led to complete remission in a patient with pure red cell aplasia. <b>2013</b> , 98, 719-22	5
165	A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?. <b>2013</b> , 12, 793-4	6
164	Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. <b>2013</b> , 122, 2943-64	437
163	Post-transfusional iron overload in the haemoglobinopathies. <b>2013</b> , 336, 164-72	14
162	Management of the thalassemias. <b>2013</b> , 3,	25
161	Deferasirox's toxicity. <b>2013</b> , 382, 127-8	3
160	Cardiovascular function and treatment in $\beta$ thalassemia major: a consensus statement from the American Heart Association. <b>2013</b> , 128, 281-308	226
159	Iron: effect of overload and deficiency. <b>2013</b> , 13, 229-94	36
158	Iron-chelation therapy with oral chelators in patients with thalassemia major. <b>2013</b> , 18, 50-5	10
157	Consequences and management of iron overload in sickle cell disease. <b>2013</b> , 2013, 447-56	90
156	Comparative assessment of deferiprone and deferasirox in thalassemia major patients in the first two decades-single centre experience. <b>2013</b> , 30, 104-12	6
155	Approaches to management of beta-thalassemia intermedia. <i>Thalassemia Reports</i> , <b>2013</b> , 3, 12	2
154	Efficacy of Deferasirox for the treatment of iron overload in Chinese thalassaemia major patients: results from a prospective, open-label, multicentre clinical trial. <b>2013</b> , 23, 389-96	11
153	Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study. <i>Haematologica</i> , <b>2013</b> , 98, 1045-8	6.6 30

152	Management of myelodysplastic syndromes in adults: guidelines from the Belgian Haematological Society. <b>2013</b> , 68, 253-62	2
151	Deferasirox: appraisal of safety and efficacy in long-term therapy. <b>2013</b> , 4, 101-10	13
150	Pharmacogenetic study of deferasirox, an iron chelating agent. <b>2013</b> , 8, e64114	18
149	Korean guideline for iron chelation therapy in transfusion-induced iron overload. <b>2013</b> , 28, 1563-72	7
148	News / Ticker. <b>2014</b> , 41, 470-471	
147	News / Ticker. <b>2014</b> , 41, 326-327	
146	Metal Antagonists. <b>2014</b> , 323-337	
145	Deferasirox for managing transfusional iron overload in people with sickle cell disease. <b>2014</b> , 5, CD007477	5
144	Deferasirox for cardiac siderosis in $\beta$ -thalassaemia major: a multicentre, open label, prospective study. <b>2014</b> , 167, 423-6	6
143	Comparison of serial serum ferritin measurements and liver iron concentration assessed by MRI in adult transfused patients with sickle cell disease. <b>2014</b> , 92, 164-7	11
142	Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan. <b>2014</b> , 16, 40	104
141	Elevated total iron-binding capacity as a predictor of response to deferasirox therapy in the setting of chronic iron overload. <b>2014</b> , 100, 254-9	1
140	Recent developments centered on orally active iron chelators. <i>Thalassemia Reports</i> , <b>2014</b> , 4,	2 11
139	Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload. <b>2014</b> , 89, 391-4	59
138	An overview of current treatment strategies for $\beta$ -thalassemia. <b>2014</b> , 2, 665-679	7
137	Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. <b>2014</b> , 6, 748-73	308
136	Aplastic anemia in adolescents and young adults. <b>2014</b> , 132, 331-9	17
135	Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease. <b>2014</b> , 28, 703-27, vi	48

134	Clinical pharmacology of deferasirox. <b>2014</b> , 53, 679-94	29
133	Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes. <b>2014</b> , 14, 817-29	6
132	Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes. <b>2014</b> , 38, 557-63	51
131	Efficacy of deferasirox in children with $\beta$ thalassemia: single-center 3 year experience. <b>2014</b> , 56, 530-3	5
130	Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. <b>2014</b> , 124, 873-81	76
129	Deferasirox for managing iron overload in people with myelodysplastic syndrome. <b>2014</b> , CD007461	6
128	The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent $\beta$ thalassemia in Taiwan. <b>2015</b> , 94, 1945-52	13
127	Iron Overload. <b>2015</b> , 40-52	
126	The deferiprone and deferasirox combination is efficacious in iron overloaded patients with $\beta$ thalassemia major: A prospective, single center, open-label study. <b>2015</b> , 62, 1592-6	32
125	News / Ticker. <b>2015</b> , 42, 268-269	
124	Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network. <b>2015</b> , 94, 336-42	6
123	Deferasirox Decreases Liver Iron Concentration in Iron-Overloaded Patients with Myelodysplastic Syndromes, Aplastic Anemia and Other Rare Anemias. <b>2015</b> , 134, 233-42	16
122	Non transferrin bound iron (NTBI) in acute leukemias throughout conventional intensive chemotherapy: kinetics of its appearance and potential predictive role in infectious complications. <b>2015</b> , 39, 88-91	16
121	Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions. <b>2015</b> , 6, 197-209	46
120	Simultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With $\beta$ Thalassemia Major: Once-daily Versus Twice-daily Administration. <b>2015</b> , 37, 1751-60	15
119	Influence of Iron Overload on Immunosuppressive Therapy in Children with Severe Aplastic Anemia. <b>2015</b> , 866, 83-9	7
118	Myelodysplastic Syndromes: Diagnosis and Treatment. <b>2015</b> , 90, 969-83	68
117	Inappropriate repeats of six common tests in a Canadian city: a population cohort study within a laboratory informatics framework. <b>2015</b> , 144, 704-12	38



116	Deferasirox effect on renal haemodynamic parameters in patients with transfusion-dependent $\beta$ thalassaemia. <b>2015</b> , 168, 882-90	26
115	Current and future treatment strategies for iron overload cardiomyopathy. <b>2015</b> , 765, 86-93	29
114	The myelodysplastic syndromes: the era of understanding. <b>2015</b> , 94, 379-90	7
113	Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy. <b>2016</b> , 6, 80-8	13
112	Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions. <b>2016</b> , 12, 201-8	13
111	Management of iron overload in hemoglobinopathies: what is the appropriate target iron level?. <b>2016</b> , 1368, 95-106	26
110	Morbidities in non-transfusion-dependent thalassemia. <b>2016</b> , 1368, 82-94	15
109	Systematic comparison of the mono-, dimethyl- and trimethyl 3-hydroxy-4(1H)-pyridones - Attempted optimization of the orally active iron chelator, deferiprone. <b>2016</b> , 115, 132-40	24
108	Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes. <b>2016</b> , 30, 349-56	13
107	Deferasirox pharmacokinetic and toxicity correlation in $\beta$ thalassaemia major treatment. <b>2016</b> , 68, 1417-1421	9
106	Fanconi Syndrome Secondary to Deferasirox in Diamond-Blackfan Anemia: Case Series and Recommendations for Early Diagnosis. <b>2016</b> , 63, 1480-3	10
105	Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment. <b>2016</b> , 96, 19-26	22
104	Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study. <b>2016</b> , 57, 23-9	17
103	Clinical monitoring and management of complications related to chelation therapy in patients with $\beta$ thalassemia. <b>2016</b> , 9, 151-68	17
102	Proximal muscular atrophy and weakness: An unusual adverse effect of deferasirox iron chelation therapy. <b>2016</b> , 26, 322-5	2
101	Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation. <b>2016</b> , 51, 89-95	27
100	Efficacy and Safety of Combined Oral Chelation With Deferiprone and Deferasirox in Children With $\beta$ Thalassemia Major: An Experience From North India. <b>2017</b> , 39, 209-213	8
99	Transfusion Therapy in Children With Sickle Cell Disease. <b>2017</b> , 39, 126-132	8

98	Deferasirox-Iron Complex Formation Ratio as an Indicator of Long-term Chelation Efficacy in $\beta$ Thalassemia Major. <b>2017</b> , 39, 185-191	4
97	Transfusion transmitted infections in frequently transfused thalassemic children living in Fayoum Governorate, Egypt: Current prevalence and risk factors. <b>2017</b> , 10, 870-874	10
96	Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes. <b>2017</b> , 62, 108-115	16
95	Is there a standard-of-care for transfusion therapy in thalassemia?. <b>2017</b> , 24, 558-564	6
94	Supportive Care in Aplastic Anemia. <b>2017</b> , 57-71	
93	Deferasirox associated with liver failure and death in a sickle cell anemia patient homozygous for the -1774delG polymorphism in the gene. <b>2017</b> , 5, 1218-1221	5
92	Deferasirox for managing iron overload in people with thalassaemia. <b>2017</b> , 8, CD007476	19
91	Neurocognitive dysfunction in children with $\beta$ thalassemia major: psychometric, neurophysiologic and radiologic evaluation. <b>2017</b> , 22, 617-622	6
90	[Transfusions in myelodysplastic syndromes]. <b>2017</b> , 24, 209-215	3
89	Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study). <b>2017</b> , 98, 97-105	4
88	One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation. <b>2017</b> , 64, 188-196	20
87	Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia. <b>2017</b> , 98, 280-288	22
86	Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS). <b>2017</b> , 52, 50-57	22
85	Survival and complication rates in patients with thalassemia major in Taiwan. <b>2017</b> , 64, 135-138	16
84	Safety and tolerability of deferasirox in pediatric hematopoietic stem cell transplant recipients: one facility's five years' experience of chelation treatment. <b>2017</b> , 8, 63177-63186	7
83	Transient Elastography (TE) is a Useful Tool for Assessing the Response of Liver Iron Chelation in Sickle Cell Disease Patients. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , <b>2018</b> , 10, e2018049	4
82	Iron Chelation Therapy as a Modality of Management. <b>2018</b> , 32, 261-275	13
81	Left Ventricular Structural and Functional Changes in Children With $\beta$ Thalassemia and Sickle Cell Disease: Relationship to Sleep-disordered Breathing. <b>2018</b> , 40, 171-177	4

80	Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents. <b>2018</b> , 35, 76	6
79	Iron toxicity - Its effect on the bone marrow. <b>2018</b> , 32, 473-479	26
78	Transitioning Patients With Iron Overload From Exjade to Jadenu. <b>2018</b> , 41, 171-175	1
77	Assessment of liver and cardiac iron overload using MRI in patients with chronic anemias in Latin American countries: results from ASIMILA study. <b>2018</b> , 23, 676-682	7
76	Prospective evaluation of the effect of deferasirox on hematologic response in transfusion-dependent patients with low-risk MDS and iron overload. <b>2018</b> , 101, 165	4
75	To chelate or not to chelate in MDS: That is the question!. <b>2018</b> , 32, 368-377	17
74	Iron overload in myelodysplastic syndromes (MDS). <b>2018</b> , 107, 55-63	50
73	Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children. <b>2018</b> , 28, 17-22	4
72	Clinical relevance of deferasirox trough levels in $\beta$ -thalassemia patients. <b>2018</b> , 45, 213-216	3
71	A Phase II, Multicenter, Single-Arm Study to Evaluate the Safety and Efficacy of Deferasirox after Hematopoietic Stem Cell Transplantation in Children with $\beta$ -Thalassemia Major. <b>2018</b> , 24, 613-618	11
70	Iron overload and chelation therapy in hemoglobinopathies. <i>Thalassemia Reports</i> , <b>2018</b> , 8,	2
69	Deferasirox: Over a Decade of Experience in Thalassemia. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , <b>2018</b> , 10, e2018066	3-2 9
68	Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias. <b>2018</b> , 16, 216	7
67	Improving Treatment for Myelodysplastic Syndromes Patients. <b>2018</b> , 19, 66	9
66	Potential Treatment of Retinal Diseases with Iron Chelators. <b>2018</b> , 11,	22
65	What is known about deferasirox chelation therapy in pediatric HSCT recipients: two case reports of metabolic acidosis. <b>2018</b> , 14, 1649-1655	7
64	Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management. <b>2018</b> , 19,	31
63	Myelodysplastic Syndromes. <b>2018</b> ,	

62	Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes. <b>2018</b> , 101, 272-282		13
61	Iron Chelation. <b>2018</b> , 105-118		
60	Thyroid hemodynamic alterations in Egyptian patients with sickle cell disease: relation to disease severity, total body iron and thyroid function. <b>2019</b> , 12, 589-596		1
59	Role of redox iron towards an increase in mortality among patients: a systemic review and meta-analysis. <b>2019</b> , 54, 87-101		
58	The challenges of handling deferasirox in sickle cell disease patients older than 40 years. <b>2019</b> , 24, 596-600		3
57	The Efficacy of Iron Chelators for Removing Iron from Specific Brain Regions and the Pituitary-Ironing out the Brain. <b>2019</b> , 12,		15
56	Combination Oral Chelation in Adult Patients With Transfusion-dependent Thalassemia and High Iron Burden. <b>2019</b> , 41, e47-e50		5
55	Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. <i>Haematologica</i> , <b>2019</b> , 104, e51-e53	6.6	27
54	Long-term safety and efficacy of deferasirox in patients with myelodysplastic syndrome, aplastic anemia and other rare anemia in Taiwan. <b>2019</b> , 24, 247-254		3
53	Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis. <b>2019</b> , 141, 32-42		12
52	Pemphigus foliaceus complicated by sepsis of the aetiology of after eating cheesecake. <b>2020</b> , 37, 111-113		
51	Myelodysplastic Syndromes. <b>2020</b> , 1798-1820.e11		
50	Management of pyruvate kinase deficiency in children and adults. <b>2020</b> , 136, 1241-1249		16
49	A 15-years follow-up of deferasirox in beta-thalassaemia major patients with iron overload. <b>2020</b> , 191, e81-e83		
48	Hepatic and cardiac iron load as determined by MRI T2* in patients with congenital dyserythropoietic anemia type I. <b>2020</b> , 99, 2507-2512		
47	Transfusional iron overload in patients with myelodysplastic syndromes: A 10-year retrospective survey from a French general hospital. <b>2020</b> , 27, 128-132		0
46	Secondary hemosiderosis presented by porphyria cutanea tarda in a kidney dialysis patient: A case report. <b>2020</b> , 8, 2050313X20907815		2
45	Iron. <b>2020</b> , 83-102		

44	Deferasirox-associated Fanconi syndrome in adult patients with transfusional iron overload. <i>Vox Sanguinis</i> , <b>2021</b> , 116, 793-797	3.1	4
43	Is Chelation Therapy a Potential Treatment for Parkinson's Disease?. <b>2021</b> , 22,		4
42	Drug safety in thalassemia: lessons from the present and directions for the future. <b>2021</b> , 20, 937-947		0
41	Novel therapies in ßthalassaemia. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> ,	3.8	0
40	Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring. <i>Scientific Reports</i> , <b>2021</b> , 11, 12581	4.9	3
39	[Consensus document for the diagnosis and treatment of pyruvate kinase deficiency]. <i>Medicina Clínica</i> , <b>2021</b> , 157, 253.e1-253.e8	1	
38	Consensus document for the diagnosis and treatment of pyruvate kinase deficiency. <i>Medicina Clínica (English Edition)</i> , <b>2021</b> , 157, 253.e1-253.e8	0.3	1
37	Clinical Use of Iron Chelators. <b>2012</b> , 591-627		3
36	EFFICACY AND SAFETY OF DEFERASIROX WHEN COMPARED TO DEFERIPRONE AS ORAL IRON CHELATING AGENT : A RANDOMIZED CONTROL TRIAL. <i>Journal of Evolution of Medical and Dental Sciences</i> , <b>2015</b> , 4, 4178-4185	0.1	2
35	Ferritin level changes and erythroid improvement in a group of adult polytransfused patients treated with Deferasirox. <i>Medicine and Pharmacy Reports</i> , <b>2018</b> , 91, 288-292	1.5	0
34	Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine. <i>Electronic Physician</i> , <b>2016</b> , 8, 2425-31	1.8	19
33	Pathological Roles of Iron in Cardiovascular Disease. <i>Current Drug Targets</i> , <b>2018</b> , 19, 1068-1076	3	61
32	An update on iron chelation therapy. <i>Blood Transfusion</i> , <b>2012</b> , 10, 411-22	3.6	119
31	Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias. <i>Blood Transfusion</i> , <b>2013</b> , 11, 108-22	3.6	14
30	Comparison of deferasirox and deferoxamine effects on iron overload and immunological changes in patients with blood transfusion-dependent ßthalassemia. <i>Asian Journal of Transfusion Science</i> , <b>2017</b> , 11, 13-17	0.5	5
29	Brazilian Guidelines for transcranial doppler in children and adolescents with sickle cell disease. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , <b>2011</b> , 33, 43-8		19
28	Aceruloplasminemia: a rare disease - diagnosis and treatment of two cases. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , <b>2011</b> , 33, 389-92		25
27	From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 752192	5.3	0

26	Iron chelation therapy in thalassemia syndromes. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , <b>2009</b> , 1, e2009034	3.2	2
25	Iron Overload. 47-60		
24	EXPERIENCE WITH DEFERASIROX FOR IRON OVERLOAD AFTER RED BLOOD CELL TRANSFUSION. <i>Japanese Journal of Transfusion and Cell Therapy</i> , <b>2012</b> , 58, 770-773	0.2	
23	Efficacy of deferasirox for the treatment of iron overload in a child affected by Juvenile Hemochromatosis. <i>Case Reports in Clinical Medicine</i> , <b>2013</b> , 02, 126-128	0.1	1
22	Myelodysplastic Syndromes. <b>2014</b> , 1907-1928.e8		
21	CHAPTER 4:Treatment of Systemic Iron Overload. <i>2-Oxoglutarate-Dependent Oxygenases</i> , <b>2016</b> , 106-152	1.8	
20	. <i>Salud Publica De Mexico</i> , <b>2017</b> , 59, 120-122	1.7	
19	Monitoring Iron Overload: Relationship between R2* Relaxometry of the Liver and Serum Ferritin under Different Therapies. <i>Journal of Clinical Imaging Science</i> , <b>2018</b> , 8, 40	1.1	0
18	Effectiveness of Deferasirox in Pediatric Thalassemia Patients: Experience from a Tertiary Care Hospital of Odisha. <i>Indian Journal of Pharmacology</i> , <b>2020</b> , 52, 172-178	2.5	2
17	Efficacy and safety of Iranian made Deferasirox (Osvera <sup>®</sup> ) in Iranian major thalassemic patients with transfusional iron overload: A one year prospective multicentric open-label non-comparative study. <i>DARU, Journal of Pharmaceutical Sciences</i> , <b>2011</b> , 19, 240-8	3.9	6
16	Renal complications of beta-thalassemia major in children. <i>American Journal of Blood Research</i> , <b>2014</b> , 4, 1-6	1.6	8
15	Optimizing Communication and Adherence to Iron Chelation Therapy From Diagnosis to Treatment in Patients With Myelodysplastic Syndromes. <i>Journal of the Advanced Practitioner in Oncology</i> , <b>2016</b> , 7, 707-717	0.7	1
14	Iron Overload in Myelodysplastic Syndromes: Pathophysiology, Consequences, Diagnosis, and Treatment. <i>Journal of the Advanced Practitioner in Oncology</i> , <b>2018</b> , 9, 392-405	0.7	7
13	[Efficacy and safety of deferasirox in aplastic anemia patients with iron overload: a single arm, multi-center,prospective study in China]. <i>Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi</i> , <b>2016</b> , 37, 1-6	0.4	1
12	[Effects of pre-immunosuppressive therapy iron overload on hematologic response of severe aplastic anemia]. <i>Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi</i> , <b>2016</b> , 37, 324-8	0.4	
11	Combination Therapies in Iron Chelation. <i>Thalassemia Reports</i> , <b>2014</b> , 4, 12-15	2	1
10	Effects of dual chelation therapy with deferasirox and deferoxamine in patients with beta thalassaemia major.. <i>Vox Sanguinis</i> , <b>2022</b> ,	3.1	1
9	Characterisation of individual ferritin response in patients receiving chelation therapy.. <i>British Journal of Clinical Pharmacology</i> , <b>2022</b> ,	3.8	0

8	Two trade names of deferasirox (Osveral <sup>®</sup> and Exjade <sup>®</sup> ) in reduction of iron overload parameters in major beta-thalassemia patients: A randomized open labeled clinical trial.. <i>Caspian Journal of Internal Medicine</i> , <b>2022</b> , 13, 61-69	1	
7	Efficacy and Tolerability of Twice-Daily Dosing Schedule of Deferasirox in Transfusion-Dependent Paediatric Beta-Thalassaemia Patients: A Randomized Controlled Study.. <i>Journal of Pharmacy Practice</i> , <b>2022</b> , 8971900211038301	1.3	1
6	Dose of deferasirox correlates with its effects, which differ between low-risk myelodysplastic syndrome and aplastic anaemia. <i>Journal of Clinical Pharmacy and Therapeutics</i> ,	2.2	
5	Understanding the Potential and Risk of Bacterial Siderophores in Cancer. <i>Frontiers in Oncology</i> , 12,	5.3	1
4	Lower-risk myelodysplastic syndromes: Current treatment options for anemia.		1
3	An evaluation of mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency. 1-11		0
2	Understanding the Association between Red Blood Cell Transfusion Utilization and Humanistic and Economic Burden in Patients with $\beta$ Thalassemia from the Patients' Perspective. <b>2023</b> , 12, 414		0
1	Clinical Challenges with Iron Chelation in Beta Thalassemia. <b>2023</b> , 37, 379-391		0